pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$GLUEMonte Rosa Therapeutics, Inc.

$GLUE9.1600+0.99%
Boston, MA, USupdated 7h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 1: 1Phase 2: 1
1Phase 11Phase 2
Phase 2
MRT-2359
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1
MRT-8102
Inflammation

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$GLUE9.1600+0.99%
14d ago
Monte Rosa Therapeutics, Inc. earnings
Monte Rosa Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase2Study of Oral MRT-2359 With Apalutamide in Prostate Cancerrecruitingn=25
  • phase2Study of Oral MRT-2359 in Selected Cancer Patientsactive not recruitingn=174
  • phase1A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPrecruitingn=100
  • phase1First-in-human Study of MRT-6160 in Healthy Subjectscompletedn=108
🐶 Hiring Signal
No open roles indexed yet — view Monte Rosa Therapeutics, Inc. jobs →

News

  • Novo’s troubled cardio drug could find niche in less sick patients
    At the American Heart Association conference, investigators were supportive of further studying Novo’s IL-6 inhibitor ziltivekimab in patients with less severe cardiovascular and kidney disease.
    biospace · 9d ago
  • Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
    Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures…
    biospace · 13d ago
  • Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis
    Evommune has paid $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular glue degrader development that’s also being pursued by Novartis.
    fiercebiotech · 13d ago
  • This week in charts: Moderna’s massive stock run
    The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
    biopharma_dive · 1mo ago
  • STAT+: FDA adcomm members’ ties to industry under scrutiny
    New research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…
    stat · 1mo ago
  • STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
    Patient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.
    stat · 1mo ago
  • The 2026 Biotech Graveyard
    Fierce’s biotech graveyard is an annual tradition in which we remember all the companies we lost over the past year. While we're embracing the spooky spirit of Halloween, we hope the sad stories of…
    fiercebiotech · 1mo ago
  • STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
    Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
    stat · 1mo ago
  • STAT+: Roche goes beyond licensing in deal with Chinese biotech
    Roche is partnering with Chinese startup Defand Therapeutics to discover new medicines.
    stat · 1mo ago
  • STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
    Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.
    stat · 1mo ago
view all news mentions →
identifiers
ticker
$GLUE
SEC CIK
0001826457
country
US
source
sec_tickers
top tags
DLBCL1Immunology1Oncology1Prostate Cancer1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?